5,348 results match your criteria: "German Center for Neurodegenerative Diseases DZNE[Affiliation]"

Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease.

Alzheimers Res Ther

September 2024

Department of Diagnostic Radiology, Clinical Sciences, Lund University, Klinikgatan 13B, Lund, SE-22242, Sweden.

Article Synopsis
  • The medial temporal lobe (MTL), thought to be relatively unaffected in early-onset Alzheimer's disease (EOAD), was examined in detail to understand atrophy patterns among different age groups of Alzheimer's patients.
  • The study included participants with memory issues and abnormal brain scans, comparing 41 EOAD individuals under 65 years old with 154 late-onset Alzheimer's (aLOAD) patients aged 70 or older, alongside cognitively healthy controls.
  • Findings revealed that both EOAD and aLOAD groups had smaller MTL regions compared to controls, with specific differences in brain structure and pathology but no significant differences in tau pathology levels between the two Alzheimer's groups.
View Article and Find Full Text PDF

Neuroligin-2 (Nlgn2) is a key synaptic adhesion protein at virtually all GABAergic synapses, which recruits GABARs by promoting assembly of the postsynaptic gephyrin scaffold. Intriguingly, loss of Nlgn2 differentially affects subsets of GABAergic synapses, indicating that synapse-specific interactors and redundancies define its function, but the nature of these interactions remain poorly understood. Here we investigated how Nlgn2 function in hippocampal area CA1 is modulated by two proposed interaction partners, MDGA1 and MDGA2.

View Article and Find Full Text PDF

Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants With Genetic Frontotemporal Dementia.

Neurology

October 2024

From the Department of Neurology (S. Schönecker, A.D., O.W., C.P., E.W., J.V., S.V.L., A. Brauer, G.U.H., J.L.), LMU University Hospital, LMU Munich, Germany; Department of Signal Theory Networking and Communications (F.J.M.-M., J.-M.G.S.), Andalusian Research Institute in Data Science and Computational Intelligence (DasCI), University of Granada, Spain; Institute for Stroke and Dementia Research (J.D., N.F.), LMU University Hospital, LMU Munich; Munich Cluster for Systems Neurology (SyNergy) (N.F., G.U.H., J.L.), Germany; Institute of Neuroscience and Physiology and Department of Psychiatry and Neurochemistry (N.F.), The Sahlgrenska Academy, University of Gothenburg, Mölndal and Gothenburg, Sweden; German Center for Neurodegenerative Diseases (DZNE) (J.V., G.U.H., J.L.), Munich, Germany; Dementia Research Centre (A. Bouzigues, L.L.R., P.H.F., E.F.-B., J.D.R.), Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Neurology (J.C.v.S., L.C.J., H.S.), Erasmus Medical Centre, Rotterdam, the Netherlands; Alzheimer's disease and Other Cognitive Disorders Unit (R.S.-V.), Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Spain; Clinique Interdisciplinaire de Mémoire (R.L.), Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Canada; Department of Neurobiology, Care Sciences and Society (C.G.), Center for Alzheimer Research, Division of Neurogeriatrics, Bioclinium, Karolinska Institutet; Unit for Hereditary Dementias (C.G.), Theme Inflammation and Aging, Karolinska University Hospital, Solna, Sweden; Fondazione Ca' Granda (D.G.), IRCCS Ospedale Policlinico, Milan; Centro Dino Ferrari (D.G.), University of Milan, Italy; Laboratory for Cognitive Neurology (R.V.), Department of Neurosciences, KU Leuven; Neurology Service (R.V.), University Hospitals Leuven; Leuven Brain Institute (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.d.M.), University of Lisbon, Portugal; Fondazione IRCCS Istituto Neurologico Carlo Besta (P.T.), Milano, Italy; University Hospital of Coimbra (HUC) (I.S.), Neurology Service, Faculty of Medicine, and Center for Neuroscience and Cell Biology (I.S.), Faculty of Medicine, University of Coimbra, Portugal; Division of Psychology Communication and Human Neuroscience Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Department of Nuclear Medicine (A.G.), Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen; Department of Geriatric Medicine (A.G.), Klinikum Hochsauerland, Arnsberg, Germany; Department of Neurofarba (S. Sorbi), University of Florence; IRCCS Fondazione Don Carlo Gnocchi (S. Sorbi), Florence, Italy; Department of Neurology (M.O.), University of Ulm, Germany; Univ Lille (F.P.); Inserm 1172 (F.P.), Lille; CHU (F.P.), CNR-MAJ, Labex Distalz, LiCEND Lille, France; Department of Psychiatry (S.D.), McGill University Health Centre, and McConnell Brain Imaging Centre (S.D.), Montreal Neurological Institute, McGill University, Montreal, Québec, Canada; Nuffield Department of Clinical Neurosciences (C.B.), Medical Sciences Division, University of Oxford; Department of Brain Sciences (C.B.), Imperial College London, United Kingdom; Sorbonne Université (I.L.B.), Paris Brain Institute, Institut du Cerveau, ICM, Inserm U1127, CNRS UMR 7225, Centre de Référence des Démences Rares ou Précoces (I.L.B.), IM2A, and Département de Neurologie (I.L.B.), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London; Tanz Centre for Research in Neurodegenerative Diseases (M.C.T.), and Sunnybrook Health Sciences Centre (M.M.), Sunnybrook Research Institute, University of Toronto, Ontario, Canada; Department of Clinical Neurosciences (J.B.R.), MRC Cognition and Brain Sciences Unit, and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom; Department of Neurodegenerative Diseases (M.S.), Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen; Center for Neurodegenerative Diseases (DZNE) (M.S.), Tübingen, Germany; Cognitive Disorders Unit (F.M.), Department of Neurology, Donostia Universitary Hospital; Neuroscience Area (F.M.), Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain; Neurology Unit (B.B.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; and Department of Psychiatry and Psychotherapy (J.P.), Technical University Munich, Germany.

Background And Objectives: Behavioral and neuropsychiatric symptoms are frequent in patients with genetic frontotemporal dementia (FTD). We aimed to describe behavioral and neuropsychiatric phenotypes in genetic FTD, quantify their temporal association, and investigate their regional association with brain atrophy.

Methods: We analyzed data of pathogenic variant carriers in the chromosome 9 open reading frame 72 (), progranulin (), or microtubule-associated protein tau () gene from the Genetic Frontotemporal dementia Initiative cohort study that enrolls both symptomatic pathogenic variant carriers and first-degree relatives of known carriers.

View Article and Find Full Text PDF

Sociodemographic Variables in Offender and Non-Offender Patients Diagnosed with Schizophrenia Spectrum Disorders-An Explorative Analysis Using Machine Learning.

Healthcare (Basel)

August 2024

Forensic Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.

Article Synopsis
  • Advances in medical data and computer technology are enabling new research opportunities through machine learning (ML), which leverages complex algorithms to find patterns in large datasets.
  • ML is particularly useful for studying multifactorial issues, such as mental health and forensic psychiatry, allowing researchers to quantify the effectiveness of their statistical models.
  • The study analyzed 48 sociodemographic variables in 370 offender and 370 non-offender schizophrenia patients, using gradient boosting as the best algorithm, but found the ability to discriminate between the two groups based on these variables was limited, with an AUC of 0.65 indicating poor statistical discrimination.
View Article and Find Full Text PDF

There is an urgent need for effective disease-modifying therapeutic interventions for Alzheimer's disease (AD)-the most prevalent cause of dementia with a profound socioeconomic burden. Most clinical trials targeting the classical hallmarks of this disease-β-amyloid plaques and neurofibrillary tangles-failed, showed discrete clinical effects, or were accompanied by concerning side effects. There has been an ongoing search for novel therapeutic targets.

View Article and Find Full Text PDF

Our understanding of Alzheimer's disease (AD) has evolved from focusing solely on neurons to recognizing the role of glia. A recent study in PLOS Biology revealed that oligodendrocytes are an important source of Aβ that impairs neuronal function.

View Article and Find Full Text PDF

Background: Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA.

View Article and Find Full Text PDF

Prognostic value of Alzheimer's disease plasma biomarkers in the oldest-old: a prospective primary care-based study.

Lancet Reg Health Eur

October 2024

Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Background: Blood-based biomarkers offer a promising, less invasive, and more cost-effective alternative for Alzheimer's disease screening compared to cerebrospinal fluid or imaging biomarkers. However, they have been extensively studied only in memory clinic-based cohorts. We aimed to validate them in a more heterogeneous, older patient population from primary care.

View Article and Find Full Text PDF

Background: The policies and mission statements of nursing homes support the implementation of person-centred dementia care. The Dementia Policy Questionnaire assesses the content of person-centred dementia care in policies. To date, it is unknown whether these policies exist exclusively in dementia care units and whether the policies are consistent with the mission statements of nursing homes.

View Article and Find Full Text PDF
Article Synopsis
  • Neurofilament light chain (NfL) levels serve as a key biomarker for neuro-axonal damage in neurodegenerative disorders, and understanding the genetics behind these levels can reveal important molecular mechanisms.
  • A meta-analysis of genome-wide association studies identified significant genetic loci associated with blood NfL levels in both European and African American populations, highlighting two key regions.
  • The study also indicated that a higher polygenic risk score for NfL correlates with increased levels of other neurodegenerative biomarkers and suggests lower kidney function may lead to elevated NfL levels in the blood.
View Article and Find Full Text PDF

Progressive supranuclear palsy (PSP), a rare Parkinsonian disorder, is characterized by problems with movement, balance, and cognition. PSP differs from Alzheimer's disease (AD) and other diseases, displaying abnormal microtubule-associated protein tau by both neuronal and glial cell pathologies. Genetic contributors may mediate these differences; however, the genetics of PSP remain underexplored.

View Article and Find Full Text PDF

Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis.

Neurol Neuroimmunol Neuroinflamm

November 2024

From the Department of Neuroscience (G.S., S.F., A.E.), Università Cattolica del Sacro Cuore, Rome, Italy; German Center for Neurodegenerative Diseases (DZNE) Berlin (G.S.), Berlin, Germany; Nuffield Department of Clinical Neurosciences (A.V., B.S., L.W.J.), University of Oxford; Fluidic Analytics Ltd (S.D.), The Paddocks Business Centre, Cambridge, United Kingdom; and Department of Neurosciences (V.D.), Drugs and Child Health, University of Florence, Italy.

Background And Objectives: In this retrospective longitudinal study, we aimed at exploring the role of (a) MuSK-immunoglobulin G (IgG) levels, (b) predominant MuSK-IgG subclasses, and (c) antibody affinity as candidate biomarkers of severity and outcomes in MuSK-MG, using and comparing different antibody testing techniques.

Methods: Total MuSK-IgGs were quantified with radioimmunoassay (RIA), ELISA, flow cytometry, and cell-based assay (CBA) serial dilutions using HEK293 cells transfected with MuSK-eGFP. MuSK-IgG subclasses were measured by flow cytometry.

View Article and Find Full Text PDF

Thalamic brain areas play an important role in adaptive behaviors. Nevertheless, the population dynamics of thalamic relays during learning across sensory modalities remain unknown. Using a cross-modal sensory reward-associative learning paradigm combined with deep brain two-photon calcium imaging of large populations of auditory thalamus (medial geniculate body, MGB) neurons in male mice, we identified that MGB neurons are biased towards reward predictors independent of modality.

View Article and Find Full Text PDF

Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.

J Parkinsons Dis

October 2024

Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tübingen, Germany.

Background: Prior investigations have elucidated pathophysiological interactions involving blood coagulation and neurodegenerative diseases. These interactions pertain to age-related effects and a mild platelet antiaggregant function of exogenous α-Synuclein.

Objective: Our study sought to explore whether cerebrospinal fluid (CSF) levels of tissue factor (TF), the initiator of the extrinsic pathway of hemostasis, differ between controls (CON) compared to patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB), considering that these conditions represent a spectrum of α-Synuclein pathology.

View Article and Find Full Text PDF

Diagnosis of the fatal neurodegenerative disease amyotrophic lateral sclerosis is challenging. Neurofilaments, indicative of neuronal damage, along with creatine kinase, creatinine, myoglobin, and troponin T, representing muscular damage, have been identified as promising fluid biomarkers. This study aims to comprehensively assess and compare their diagnostic and prognostic potential in a 'real-world' cohort of patients with amyotrophic lateral sclerosis.

View Article and Find Full Text PDF

Objective: To determine whether an accelerated protocol of 48 Hz cerebellar repetitive transcranial magnetic stimulation results in improved motor function in individuals with Parkinson's disease.

Methods: In this double-blind randomized sham-controlled study, 35 individuals with Parkinson's disease and stable medical treatment were randomized to either sham or verum transcranial magnetic stimulation. The stimulation was applied bilaterally and medial over the cerebellum and comprised a novel accelerated protocol encompassing two sessions per day on 5 consecutive days.

View Article and Find Full Text PDF

Background: Microglial activation is one hallmark of Alzheimer disease (AD) neuropathology but the impact of the regional interplay of microglia cells in the brain is poorly understood. We hypothesized that microglial activation is regionally synchronized in the healthy brain but experiences regional desynchronization with ongoing neurodegenerative disease. We addressed the existence of a microglia connectome and investigated microglial desynchronization as an AD biomarker.

View Article and Find Full Text PDF

In recent years, many neuroimaging studies have applied artificial intelligence (AI) to facilitate existing challenges in Parkinson's disease (PD) diagnosis, prognosis, and intervention. The aim of this systematic review was to provide an overview of neuroimaging-based AI studies and to assess their methodological quality. A PubMed search yielded 810 studies, of which 244 that investigated the utility of neuroimaging-based AI for PD diagnosis, prognosis, or intervention were included.

View Article and Find Full Text PDF

Background: While several studies in cerebral amyloid angiopathy (CAA) focus on cognitive function, data on neuropsychiatric symptoms (NPS) and lifelong mental activities in these patients are scarce. Since NPS are associated with functional impairment, faster cognitive decline and faster progression to death, replication studies in more diverse settings and samples are warranted.

Methods: We prospectively recruited n = 69 CAA patients and n = 18 cognitively normal controls (NC).

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how copy number variations (CNVs) affect the development of Parkinson's disease (PD), aiming to identify new genetic mechanisms linked to sporadic cases of the disease.
  • Utilizing data from over 11,000 PD patients and nearly 9,000 controls, the researchers discovered 14 significant CNV loci associated with PD, including various gene duplications and deletions.
  • The research highlights a higher prevalence of CNVs in specific PD-related genes among patients and suggests that certain CNVs, especially those involving the gene, may lead to earlier onset of the disease in early-onset PD cases.
View Article and Find Full Text PDF

The accumulation of senescent cells is thought to play a crucial role in aging-associated physiological decline and the pathogenesis of various age-related pathologies. Targeting senescence-associated cell surface molecules through immunotherapy emerges as a promising avenue for the selective removal of these cells. Despite its potential, a thorough characterization of senescence-specific surface proteins remains to be achieved.

View Article and Find Full Text PDF

Repeat expansions in FGF14 cause autosomal dominant late-onset cerebellar ataxia (SCA27B) with estimated pathogenic thresholds of 250 (incomplete penetrance) and 300 AAG repeats (full penetrance), but the sequence of pathogenic and non-pathogenic expansions remains unexplored. Here, we demonstrate that STRling and ExpansionHunter accurately detect FGF14 expansions from short-read genome data using outlier approaches. By combining long-range PCR and nanopore sequencing in 169 patients with cerebellar ataxia and 802 controls, we compare FGF14 expansion alleles, including interruptions and flanking regions.

View Article and Find Full Text PDF

Purpose: This work demonstrates a new variant of the 3DREAM sequence for whole-brain mapping employing a three-dimensional (3D) stack-of-spirals readout. The spiral readout reduces the echo train length after the STEAM preparation in order to overcome the significant blurring in STE* images due to the decreasing STE* signal with each excitation pulse.

Methods: The 3DREAM sequence rapidly acquires two contrasts to calculate whole-brain flip angle maps.

View Article and Find Full Text PDF

Background: Diabetes mellitus (DM), prediabetes, and insulin resistance are highly prevalent in patients with ischemic stroke (IS). DM is associated with higher risk for poor outcomes after IS.

Objective: Investigate the risk of recurrent vascular events and mortality associated with impaired glucose metabolism compared to normoglycemia in patients with IS and transient ischemic attack (TIA).

View Article and Find Full Text PDF